An interventional study of SmoothCore Technology Orthokeratology Combined with M.O.V.E. Lenses and M.O.V.E. Lenses Alone in High Myopia, sponsored by Beijing Tongren Hospital. Not yet recruiting. Open to participants aged 8 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Beijing Tongren Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Myopia by Beijing Tongren Hospital — 10 open to participants now, 11 under way, none of them phase 3. Myopia · Beijing Tongren Hospital.
Among the 22 studies in Myopia by Beijing Tongren Hospital, this one is the 13th largest by planned enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2026, is one of 14 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 19th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →10 of the 22 studies in Myopia by Beijing Tongren Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tongren Hospital · Sites in China
Healthy volunteers
Beijing Tongren Hospital · Sites in China
Ages 6–16
Beijing Tongren Hospital · Sites in China
Ages 6–9 · Healthy volunteers
Beijing Tongren Hospital · Sites in China
Ages 7–18 · Healthy volunteers
Beijing Tongren Hospital · Sites in China
Ages 6–12 · Healthy volunteers
By country, each count listing its studies:
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 8 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 120 across the 17 interventional studies, 2,000 across the 5 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tongren Hospital is the lead sponsor of 165 studies on the registry; 54 are open to participants now.
4 of the studies in Myopia by Beijing Tongren Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07724210Beijing Tongren HospitalEffectiveness of Digital Defocus Vision Training With Low-Concentration Atropine on the Prevention and Control of Myopia in Children: A Clinical Study | 2026-12-31 |
| NCT05786586Beijing Tongren Hospital650nm Low-level Red-light for Myopia Control and Prevention in Children | 2026-12-31 |
| NCT07412678Beijing Tongren HospitalEvaluation of the Efficacy of Red Light in Adult Patients With High and Extreme Myopia | 2027-03-11 |
| NCT07946094Beijing Tongren HospitalEvaluation of the Effect of Comprehensive Myopia Control Interventions on Myopia Prevention and Control | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies in Myopia by Beijing Tongren Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to determine whether a combination of overnight orthokeratology lenses and daytime myopia-control spectacles is more effective than myopia-control spectacles alone in slowing myopia progression and improving vision-related quality of life in children aged 8-14 years with high myopia. Orthokeratology lenses are contact lenses designed to temporarily reshape the anterior surface of the eye during sleep. The study will also asess the safety of this combined treatment.The main questions it seeks to answer are:
The researchers will compare SmoothCore orthokeratology lenses combined with M.O.V.E. myopia-control spectacle lenses with the same spectacle lenses used alone. A total of 100 children will be randomly assigned to one of the two groups, with an equal chance of being allocated to either group.
Participants will:
Childhood high myopia is associated with continued axial elongation and an increased lifetime risk of sight-threatening ocular disease. Overnight orthokeratology temporarily reshapes the cornea and may slow axial elongation; however, children with high myopia may still require daytime spectacles to correct residual refractive error. Whether combining orthokeratology with myopia-control spectacles offers additional benefit over myopia-control spectacles alone remains uncertain.
This single-center, prospective, parallel-group, exploratory superiority randomized controlled trial will enroll 100 children aged 8-14 years with high myopia. Participants will be randomized in a 1:1 ratio using a computer-generated, variable-block sequence stratified by age. Participants, guardians, and lens-fitting personnel will be unmasked; outcome assessors and statistical analysts will remain masked until database lock.
The combined-treatment group will wear SmoothCore orthokeratology lenses for at least 8 hours per night on at least 5 nights per week, together with M.O.V.E. myopia-control spectacles for at least 10 hours per day. Orthokeratology will provide partial correction according to the approved correction range and individual ocular characteristics, while daytime spectacles will correct any residual refractive error. The spectacle-only group will wear the same spectacle lens model and optical design, with full central refractive correction, for at least 10 hours per day. Study lenses will be supplied by the study site and used within their NMPA-approved indications. Prescriptions will be adjusted according to standardized criteria.
Participants will undergo screening and assessments at baseline, 1 day, 1 week, and 1, 3, 6, and 12 months. Adherence will be assessed using lens-wear diaries, questionnaires, and where applicable, contact lens care-solution usage records. Ocular safety assessments will include slit-lamp examination, corneal staining and topography, intraocular pressure measurement, corneal endothelial assessment, and adverse event monitoring. Vision-related quality of life and lens satisfaction will also be evaluated.
The primary outcome is the change in study-eye axial length from baseline to month 12 and change in vision-related quality of life at 3, 6 and 12 months. The study eye will be selected before randomization: the qualifying eye if only one meets the high-myopia criterion, or the right eye if both qualify. Additional outcomes include refractive and corneal changes, adherence, quality of life, satisfaction, and safety. Refractive outcomes will be interpreted as exploratory because orthokeratology alters corneal shape.
The primary analysis will follow the intention-to-treat principle using analysis of covariance adjusted for baseline axial length, age, and baseline spherical equivalent refraction. Sensitivity and supportive analyses will assess the robustness of the findings. Safety will be analyzed according to treatment actually received among participants who receive at least one study intervention.
The criteria were revised on the registry on Oct 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: SmoothCore Technology Orthokeratology Combined with M.O.V.E. Lenses
Device: M.O.V.E. Lenses Alone
Participants will wear NMPA-approved orthokeratology (OK) lenses suitable for their corneal characteristics and refractive status overnight, with a target wearing schedule of at least 5 nights per week and at least 8 hours per night. Partial correction will be provided according to the approved correction range, corneal topography, and refractive status. During waking hours, participants will wear the study-specified model of M.O.V.E. spectacle lenses to correct residual refractive error following orthokeratology and provide the intended optical defocus, with a target wearing time of at least 10 hours per day. Prescriptions for both the OK lenses and M.O.V.E. lenses will be determined by trained study ophthalmologists or optometrists in accordance with standardized operating procedures.
Participants will wear M.O.V.E. spectacle lenses of the same brand, model, and optical design as the daytime lenses used in the experimental group. The central prescription will provide full correction based on cycloplegic refraction, with a target wearing time of at least 10 hours per day. Visual acuity and refractive status will be reassessed at scheduled visits, and the spectacle prescription will be updated when the predefined adjustment criteria are met.
Axial elongation
Change in axial length from baseline to month 12 (ΔAL, mm) serves as the primary outcome measure. Axial length will be measured in millimeters using the LENSTAR LS 900 optical biometer,
Time frame: Baseline and months 3, 6, 12
Vision-related quality of life (Pediatric Refractive Error Profile 2,PREP2)
Scores on the Pediatric Refractive Error Profile 2 (PREP2) range from 0 to 100, with higher scores indicating better vision-related quality of life.
Time frame: Baseline and months 1, 3, 6 and 12
Cycloplegic refraction
Cycloplegic refraction will be measured using an autorefractor after cycloplegia and calculated as spherical power plus one-half of cylindrical power, in diopters (D). Change will be calculated as the follow-up value minus the baseline value.
Time frame: Baseline and months 6, 12
Corneal higher-order aberrations
Anterior corneal higher-order aberrations will be measured using the Pentacam system. The root mean square (RMS) of Zernike terms of orders 3 through 6 will be calculated over a standardized 6.0 mm analysis diameter and reported in micrometers (µm).
Time frame: Baseline and months 3,6, 12
Pupil diameter
Pupil diameter will be measured using the LENSTAR LS 900 optical biometer and reported in millimeters (mm).
Time frame: Baseline and months 3,6, 12
Subfoveal choroidal thickness and choroidal vessel density
Subfoveal choroidal thickness will be measured using optical coherence tomography and reported in micrometers (µm). Flow density will be defined as the percentage of the analyzable region occupied by detected flow signal in the choriocapillaris slab. Assessments will be performed between 8:00 and 10:00 a.m. to reduce variation associated with time of day.
Time frame: Baseline and months 1, 3, 6,12
Best-corrected visual acuity (BCVA) and presenting visual acuity
The best visual acuity achievable with optimal refractive correction and presenting visual acuity, expressed as the logarithm of the minimum angle of resolution (logMAR). Scores range from -0.3 to 1.0 logMAR, with lower values indicating better visual acuity. A value of 0.0 logMAR corresponds to decimal visual acuity of 1.0.
Time frame: Baseline and months 3, 6,12
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Apr 2028, 17 months later.
Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 17 months is below that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.